Dermatologic Approaches to Pediatric Epidermolysis Bullosa: Current Standards and Emerging Strategies

Pediatric epidermolysis bullosa (EB) comprises a heterogeneous group of inherited blistering disorders defined by skin fragility, recurrent wounding, and multisystem sequelae that necessitate sustained dermatologic management across childhood. This review synthesizes pediatric-relevant evidence from thirty-three records in your dataset to characterize current standards and emerging dermatologic strategies. We categorized studies into guidance frameworks; wound and blister care (including negative- pressure interfaces and atraumatic dressings); pain and itch control relevant to frequent dressing changes and minor procedures; infection prevention and antimicrobial stewardship; procedural dermatology; surveillance for cutaneous complications; and early-phase cellular or gene-related interventions. The evidence base is dominated by guidelines, narrative and systematic syntheses, observational experience, and small case designs; randomized or blinded trials are rare, outcome definitions are often inconsistent, and pediatric comparative-effectiveness data remain limited. Publications have increased over time, reflecting expanding interest in supportive wound technologies and investigational disease-modifying approaches. Dermatologic priorities remain centered on moisture-balanced, nonadherent dressings; meticulous blister care; symptom relief; and infection vigilance, implemented through multidisciplinary pathways that anticipate mucosal and nutritional complications. Immediate opportunities include standardizing pediatric wound and symptom endpoints, embedding patient- and caregiver-reported outcome measures, and interoperable documentation of infection and healing trajectories. Future research should favor pragmatic trials of dressing systems and adjuncts, pediatric-validated pain and pruritus metrics integrated into routine workflows, and prospective safety registries for emerging therapies that capture durability, equity of access, and domain-specific adverse events in children.